How will these deals affect Medicare beneficiaries?
Certain Medicare patients will pay a copay of $50 per month for all approved uses of injectable and oral GLP-1 drugs, including diabetes and obesity treatment.
Yanuki
ARTICLE DETAIL
Trump Administration Announces Deals to Cut Obesity Drug Prices | TrumpRx Launches: Discounted Prescription Drugs? | Pfizer Beats Q4 2026 Earnings Estimates Despite Covid Product Decline | Pharma Rewiring Healthcare: DTP, DTC, and DTE Models | Trump Administration Announces Deals to Cut Obesity Drug Prices | TrumpRx Launches: Discounted Prescription Drugs? | Pfizer Beats Q4 2026 Earnings Estimates Despite Covid Product Decline | Pharma Rewiring Healthcare: DTP, DTC, and DTE Models
Health and Science / Policy
Trump Administration Announces Deals to Cut Obesity Drug Prices
The Trump administration has announced landmark deals with Eli Lilly and Novo Nordisk to significantly reduce the prices of some obesity drugs, aiming to expand access to these costly treatments. The agreements will affect Medicare and Medi...
Key Insights
- Deals with Eli Lilly and Novo Nordisk will lower prices of GLP-1 drugs on Medicare and Medicaid.
- Treatments will be offered directly to consumers at a discount via TrumpRx.gov starting January 2026.
- Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk will be $145 per month through Medicare, Medicaid, or TrumpRx.
- Existing injections like Wegovy and Zepbound will start at $350 per month on TrumpRx, decreasing to $245 over two years.
In-Depth Analysis
President Trump's administration is taking steps to lower drug costs by tying them to the lowest prices abroad. These deals with Eli Lilly and Novo Nordisk represent a significant move in this direction. The agreements ensure that Medicare will begin covering obesity drugs for some patients in mid-2026, potentially broadening the market and encouraging private insurers to follow suit.
- **Medicare Coverage Expansion:** A pilot program will cover a majority of beneficiaries under Medicare Part D, focusing on those who are overweight with a BMI greater than 27 or with prediabetes/cardiovascular disease, those with obesity and uncontrolled hypertension/kidney disease/heart failure, and patients with severe obesity.
- **Pricing Structure:** Novo Nordisk's oral version of Wegovy and Eli Lilly's orforglipron will be available at $145 per month for starting doses. Existing injections will initially cost $350 per month, reducing to $245 over time.
- **Broader Implications:** These deals align with Trump's 'most favored nation' policy, where drugmakers offer discounts in exchange for exemptions from planned pharmaceutical tariffs. Eli Lilly and Novo Nordisk have also pledged to provide most favored nation pricing on new medicines and share savings from foreign drug price increases.
These changes could have a substantial impact on the accessibility and affordability of obesity treatments, potentially improving health outcomes for millions of Americans.
FAQ
When will these changes take effect?
Medicare coverage for obesity drugs is expected to begin in mid-2026, with TrumpRx.gov launching in January 2026.
Takeaways
- The Trump administration has secured deals to lower obesity drug prices, potentially making these treatments more accessible.
- Medicare will begin covering obesity drugs for some patients in 2026.
- New drugs and existing injections will see significant price reductions through Medicare, Medicaid, and TrumpRx.gov.
Discussion
What do you think about the potential impact of these drug price cuts? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.